

**Committee on Science, Space, and Technology**

**U.S. House of Representatives**

Witness Disclosure Requirement - "Truth in Testimony"  
Required by House Rule XI, Clause 2(g)(5)

1. <b>Your Name</b> Sharon M. Moe, MD, FASN		
2. <b>Are you testifying on behalf of the Federal, or a State or local government entity?</b>	Yes	No <input checked="" type="checkbox"/>
3. <b>Are you testifying on behalf of an entity that is not a government entity?</b>	Yes <input checked="" type="checkbox"/>	No
4. <b>Other than yourself, please list which entity or entities you are representing:</b> The American Society of Nephrology		
5. <b>Please list any Federal grants or contracts (including subgrants or subcontracts) that you or the entity you represent have received on or after October 1, 2011:</b> I have received research funding from the Veterans Health Administration in the form of Merit Review Grants since 2003. The funding falls under the mechanism of vascular calcification in dialysis patients. See Appendix A for more.		
6. <b>If your answer to the question in item 3 in this form is "yes," please describe your position or representational capacity with the entity(ies) you are representing:</b> I am the current president of the American Society of Nephrology.		
7. <b>If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?</b>	Yes	No
8. <b>If the answer to the question in item 3 is "yes," please list any Federal grants or contracts (including subgrants or subcontracts) that were received by the entities listed under the question in item 4 on or after October 1, 2011, that exceed 10 percent of the revenue of the entities in the year received, including the source and amount of each grant or contract to be listed:</b> Federal grants and contracts to ASN have not exceeded 10% of the society's revenues in any given year. In total, ASN has received \$119,850 in grant funding, while providing more than \$7,150,000 of the society's funds to support grants for the next generation of nephrologists. Among not-for-profits, ASN is the largest funder of kidney research. In fact, ASN has supported research since 1996 and granted more than \$30 million to medical students, fellows, and young investigators.		

I certify that the above information is true and correct.

Signature: \_\_\_\_\_

*Sharon Moe*

Date: \_\_\_\_\_

*4/7/14*

## Appendix A

I have received research funding from the National Institutes of Health (NIH) in the form of 4 grants since 2011:

1. Principal Investigator: NIH R01 grant through the NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases that is currently active entitled "Bisphosphonates in the treatment of CKD-Mineral Bone Disorder"
2. Principal Investigator: NIH K24 (mid-career mentoring award) through the NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for 10 years that ran through March 31, 2012, on "musculoskeletal disorders in dialysis patients"
3. Principal Investigator: NIH U34 through NIDDK from July 1, 2011, through December 30, 2012, entitled "Randomized Trial of Active Vitamin, Cholecalciferol, and Placebo for the treatment of CKD-MBD"
4. Co-Investigator on Indiana Clinical Translational Science Award. Currently in year six and my role is active as a leader of a committee: Project Development Team which serves to mentor faculty.

None of these grants are related to novel technologies related to kidney dialysis.